Article

Research interest grows in BRCA-mutation positive cancers

Elizabeth whittington blog image

As research is showing us, individuals with BRCA mutation-positive breast cancer have a very unique disease when compared with other breast cancers, even among those with triple-negative disease. While a class of drugs called PARP inhibitors has garnered attention in this patient population, a new class called CDK (cyclin-dependent kinases) inhibitors is emerging that may be just as promising.In this phase 1 study, two drugs are combined for a synergistic effect. Sapacitabine is a drug that induces a single strand break in the double-stranded DNA of the cancer cell. In cells with BRCA mutations, the DNA is unable to repair itself and the cell dies. The second drug, seliciclib, which is a CDK inhibitor, also disrupts cell repair mechanisms, but also blocks a pro-survival protein. When seliciclib is added to sapacitabine, the effect is maximized. Last year at the American Society of Clinical Oncology's annual meeting, researchers published preliminary results of the trial. In a typical phase 1 study, researchers give varying doses of the treatment to determine the highest and safest dose for patients. Of the 19 patients who received the maximum tolerated dose, three patients had a partial response and one had stable disease. Six other patients saw their tumor stabilize at other doses.Results presented today at AACR to the press include 38 patients now enrolled in the trial who have various solid tumor types. The full presentation will be reported on Tuesday. The initial response of the combination was significant in patients with BRCA-mutation cancers. Four of the patients, who have BRCA mutation-positive pancreatic, breast or ovarian cancer, have experienced at least some shrinkage in their tumors. Eight additional patients had no tumor growth for at least 12 weeks. Several patients had prior treatment with PARP inhibitors and platinum-based chemotherapies, but tumor responses were seen mostly in those who had not received a prior PARP inhibitor. Side effects from seliciclib included fatigue and nausea and sapacitabine increased the risk of neutropenia.Although there are no specific treatments approved for patients with BRCA-mutation cancers, this combination may be promising, along with the potential for PARP inhibitors. "We finally have some drug classes that are addressing these [BRCA-mutation positive] patients," says George Shapiro, one of the lead investigators of the study from Dana-Farber Cancer Institute.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Related Content